Halting the progression of heart failure: Finding the optimal combination therapy

Article Type
Changed
Tue, 12/18/2018 - 15:26
Display Headline
Halting the progression of heart failure: Finding the optimal combination therapy
Article PDF
Author and Disclosure Information

Jan N. Basile, MD
Associate Professor of Medicine, Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC

Address: Jan N. Basile, MD, Ralph H. Johnson VA Medical Center, 109 Bee St, Charleston, SC 29403

Dr. Basile has received grant support from Novartis Pharmaceuticals, has served as a consultant for Forest Pharmaceuticals, and is on the speakers’ bureau for AstraZeneca, Merck, Novartis Pharmaceuticals, Pfizer, Solvay, and Wyeth-Ayerst.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Issue
Cleveland Clinic Journal of Medicine - 69(2)
Publications
Topics
Page Number
104-105, 109-110, 112
Sections
Author and Disclosure Information

Jan N. Basile, MD
Associate Professor of Medicine, Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC

Address: Jan N. Basile, MD, Ralph H. Johnson VA Medical Center, 109 Bee St, Charleston, SC 29403

Dr. Basile has received grant support from Novartis Pharmaceuticals, has served as a consultant for Forest Pharmaceuticals, and is on the speakers’ bureau for AstraZeneca, Merck, Novartis Pharmaceuticals, Pfizer, Solvay, and Wyeth-Ayerst.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Author and Disclosure Information

Jan N. Basile, MD
Associate Professor of Medicine, Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC

Address: Jan N. Basile, MD, Ralph H. Johnson VA Medical Center, 109 Bee St, Charleston, SC 29403

Dr. Basile has received grant support from Novartis Pharmaceuticals, has served as a consultant for Forest Pharmaceuticals, and is on the speakers’ bureau for AstraZeneca, Merck, Novartis Pharmaceuticals, Pfizer, Solvay, and Wyeth-Ayerst.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 69(2)
Issue
Cleveland Clinic Journal of Medicine - 69(2)
Page Number
104-105, 109-110, 112
Page Number
104-105, 109-110, 112
Publications
Publications
Topics
Article Type
Display Headline
Halting the progression of heart failure: Finding the optimal combination therapy
Display Headline
Halting the progression of heart failure: Finding the optimal combination therapy
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media